CTI BioPharma

Shire bids CTI and its troubled myelofibrosis drug adieu, buying its way out of a deal
Shire bids CTI and its troubled myelofibrosis drug adieu, buying its way out of a deal
Endpoints
Shire
myelofibrosis
CTI BioPharma
Baxalta
M&A
pacritinib
Flag link:
Shire wants out of that $172M Baxalta deal with CTI Bio
Shire wants out of that $172M Baxalta deal with CTI Bio
Endpoints
Shire
Baxalta
CTI BioPharma
M&A
Flag link:
4 BioPharma Movers That Cannot Be Ignored
4 BioPharma Movers That Cannot Be Ignored
24/7 Wall St
CTI BioPharma
Incyte
Biocryst
NxStage Medical
Flag link:
FDA puts full clinical hold on CTI BioPharma's blood cancer drug
FDA puts full clinical hold on CTI BioPharma's blood cancer drug
Yahoo/Reuters
CTI BioPharma
FDA
blood cancer
pacritinib
Flag link:
Baxalta drops, CTI nosedives after patient deaths & adverse events prompt FDA partial hold
Baxalta drops, CTI nosedives after patient deaths & adverse events prompt FDA partial hold
BioPharma Dive
Baxalta
Shire
CTI BioPharma
pacritinib
JAK inhibitors
Flag link:
Three Small Companies With Big Name Partnerships In Immuno-Oncology
Three Small Companies With Big Name Partnerships In Immuno-Oncology
Yahoo
immuno-oncology
Peregrine Pharmaceuticals
AstraZenca
MabVax Therapeutics
Juno Therapeutics
CTI BioPharma
Flag link:
How 6 ASCO Biotech Winners Are Focusing on the Future of Cancer
How 6 ASCO Biotech Winners Are Focusing on the Future of Cancer
24/7 Wall St
biotech
ASCO
Immunogen
Exelixis
Oncothyreon
CTI BioPharma
Immunomedics
Vascular Biogenics
Flag link:
16 Biotech Stocks Moving Off The ASCO Conference
16 Biotech Stocks Moving Off The ASCO Conference
Yahoo/Benzinga
biotech
ASCO
Bristol-Myers Squibb
Immunogen
Oncothyreon
Clovis Oncology
CTI BioPharma
Exelixis
Roche
Amgen
AstraZeneca
Puma Biotechnology
Vascular Biogenics
Immunomedics
Momenta
Eli Lilly
Juno Therapeutics
Express Scripts
Flag link:
ASCO '15 Report Card: Grading Biotech and Drug Stocks at Cancer Drug Confab
ASCO '15 Report Card: Grading Biotech and Drug Stocks at Cancer Drug Confab
TheStreet.com
ASCO
Oncothyreon
Immunogen
Bristol-Myers Squibb
Merck
Clovis Oncology
Roche
CTI BioPharma
Celldex Therapeutics
Puma Biotechnology
Express Scripts
Flag link:
6 Key Cancer Winners From ASCO Presentations
6 Key Cancer Winners From ASCO Presentations
24/7 Wall St
ASCO
Immunogen
mirevtuximab soravtansine
ONT-380
Oncothyreon
cabozantinib
Exelixis
VB-111
Vascular Biogenics
Immunomedics
sacituzumab govitecan
pacritinib
CTI BioPharma
Flag link:
ASCO '15: CTI Biopharma Takes on Myelofibrosis Drug Rival
ASCO '15: CTI Biopharma Takes on Myelofibrosis Drug Rival
TheStreet.com
ASCO
CTI BioPharma
myelofibrosis
pacritinib
Jakafi
Incyte
Flag link:
Baxter and its controversial partner CTI claim a win in PhIII blood cancer study
Baxter and its controversial partner CTI claim a win in PhIII blood cancer study
Fierce Biotech
Baxter
CTI BioPharma
pacritinib
myelofibrosis
Flag link:
19 Lesser-Known Biotech Stocks With Robust Drug Pipelines
19 Lesser-Known Biotech Stocks With Robust Drug Pipelines
Yahoo/Benzinga
biotech
Threshold Pharmaceuticals
Acceleron
Spectrum Pharmaceuticals
Ultragenyx
Argos Therapeutics
OncoMed
Peregrine Pharmaceuticals
Incyte
Calithera
Array Biopharma
Theravance
Puma Biotechnology
CTI BioPharma
Orexigen
Enanta Pharmaceuticals
Sucampo
Exelixis
Cubist Pharmaceuticals
United Therapeutics
Flag link:
2015 Biotech Drug/Stock Outlook: Here's What You Need to Know
2015 Biotech Drug/Stock Outlook: Here's What You Need to Know
TheStreet.com
Biogen Idec
Bluebird Bio
Arrowhead Research
Vertex Pharmaceuticals
Cempra
CTI BioPharma
Gilead Sciences
Merck
Bristol-Myers Squibb
Sarepta Therapeutics
Neurocrine Biosciences
Flag link:
CTI BioPharma Announces Comprehensive Kinome Analysis that Demonstrates Pacritinib Inhibits Kinases Linked to a Spectrum of Blood-Related Cancers
CTI BioPharma Announces Comprehensive Kinome Analysis that Demonstrates Pacritinib Inhibits Kinases Linked to a Spectrum of Blood-Related Cancers
Yahoo/PR Newswire
CTI BioPharma
pacritinib
hematologic cancers
Flag link:
Five Biotech Firms Whose Stock-Promoting Efforts Didn't Pay Off
Five Biotech Firms Whose Stock-Promoting Efforts Didn't Pay Off
TheStreet.com
MediciNova
Agenus
CytRx
CTI BioPharma
Sunesis
Flag link:
FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis
FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis
Yahoo
pacritinib
FDA
CTI BioPharma
fast track
myelofibrosis
Flag link: